Death associated protein kinase-1 gene methylation pattern in some leukemic patients attending Zagazig University hospitals: is it a clue?

W. M. Sarhan, Y. E. Abou El-Magd, A. S. El-Shal, A. F. Abd El-Helim


Background: Leukemia is a type of cancer arising from white blood cells (WBCs) and resulting from malignant transformation of different types of white blood cell precursors. The objective was to study the DAPK-1 gene methylation pattern in leukemic patients and to through some light on its possible role as a risk factor for leukemia.

Methods: Forty-one patients diagnosed as leukemic patients and 41 age-matched healthy unrelated volunteers taken as a control group. The analysis of aberrant promoter DAPK1 gene methylation was done by specific polymerase chain reaction.

Results: The results of the present study showed that there was a significant association of methylated DAPK-1 promoter area among leukemic group than in control group Chi-square (X2) was 21.98, or value patients was 10.46 and there was a significant association when compared with the control group (p <0.001). And there was no significant association when compared according to gender Chi-square (X2) was 0.43 and (p=0.51). Our results revealed in the AML group DAPK-1 promoter area were methylated with percentage of 73.9%. or value for AML patients was 13.76 and there was a significant association when compared with the control group (p <0.001), in the ALL group 4 patients had methylated DAPK-1 promoter area with percentage of 57.1% or value for all patients was 6.47 and there was a significant association when compared with the control group (p=0.03) and in the CLL group 7 patients had methylated DAPK-1 promoter area with percentage of 63.6%. OR value for CCL patients was 8.5 and there was a significant association when compared with the control group (p=0.004). On the contrary, we didn’t observe any significant associations between DAPK-1 promoter area methylation and the type of leukemia (p = 0.65).

Conclusions: These results suggested that DAPK1 promoter methylation might play a significant role in the pathogenesis of different types of leukemia. And the DAPK1 promoter methylation has a predictive value in the prediction of leukemia occurrence. 


Leukemia, Death associated protein kinase, Pattern of methylation, Methylation specific polymerase chain reaction (MSP-PCR)

Full Text:



Ntziachristos P, Mullenders J, Trimarchi T, Aifantis I. Mechanisms of epigenetic regulation of leukemia onset and progression. Advances in Immunology. 2013;117:10.

Goldman L, Schafer AI. The acute leukemias. In: Goldman's Cecil Medicine. 24th edition. 2012.

LLS. Leukemia and lymphoma society. Disease Information and Support. Diagnosis: Lab Tests to Confirm a Diagnosis. 2012.

Capuano F, Muelleder M, Kok RM, Blom HJ, Ralser M. Cytosine DNA methylation is found in Drosophila melanogaster but absent in saccharomyces cerevisiae, schizosaccharomyces pombe and other yeast species. Analytical Chemistry.2014;86:8.

Daura OE, Cabre M, Montero MA, Paternain JL, Romeu A. Specific gene hypomethylation and cancer: new insights into coding region feature trends. Bioinformation. 2009;3(8):340-3.

Anjum R, Roux PP, Ballif BA, Gygi SP, Blenis J. The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Current Biology. 2005;15(19):1762-7.

Ogawa T, Liggett TE, Melnikov AA, Monitto CL, Kusuke D, Shiga K, et al. Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle. 2012;11(8):1656-3.

Pulling LC, Grimes MJ, Damiani LA, Juri DE, Do K, Tellez CS. et al. Dual promoter regulation of death-associated protein kinase gene leads to differentially silenced transcripts by methylation in cancer. Carcinogenesis. 2009;30(12):2023-30.

Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y. et al. DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. British journal of cancer. 2002:86(11):1817-23.

Gonzalez GP, Bello MJ, Alonso ME, Arjona D, Lomas J, Campos JM, et al. CpG island methylation status and mutation analysis of the RB1 gene essential promoter region and protein-binding pocket domain in nervous system tumours. Br J Cancer. 2003:88:109-114.

Sung SK, Young HC, Chang WH, Yoo DC, Youngkyu P. DNA Methylation Profiles of MGMT, DAPK1, hMLH1, CDH1, SHP1, and HIC1 in B-Cell Lymphomas. Korean J Pathol. 2009;43:420-7.

Ekmekci CG, Gutiérrez MI, Siraj AK, Ozbek U, Bhatia K. Aberrant methylation of multiple tumor suppressor genes in acute myeloid leukemia. Am J Hematol. 2004;77:233-40.

Ng MH, To KW, Lo KW, Chan S, Tsang KS, Cheng SH, et al. Frequent death-associated protein kinase promoter hypermethylation in multiple myeloma. Clinical Cancer Research. 2001;7(6):1724-9.

Gutierrez MI, Siraj AK, Bhargava M, Ozbek U, Banavali S, Chaudhary, et al. Concurrent methylation of multiple genes in childhood ALL: Correlation with phenotype and molecular subgroup. Leukemia. 2003;17(9):1845-50.

Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. 2009;114(13):2764-73.

Abrahamsson J, Forestier E, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. Journal of Clinical Oncology. 2011;29(3):310-5.

Choung HK, Kim YA, Lee MJ, Kim N, Khwarg SI. Multigene methylation analysis of ocular adnexal MALT lymphoma and their relationship to Chlamydophila psittaci infection and clinical characteristics in South Korea. Invest Ophthalmol Vis Sci. 2012;53:1928-35.

Bene MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European leukemia net work package 10. Leukemia. 2011;25(4):567-74.

Alberts. Molecular Biology of the Cell; 5th Edition, Garland Science, 2008.

Benderska N, Schneider SR. Transcription control of DAPK. Apoptosis. 2014;19(2):298-305.

Kissil JL, Cohen O, Raveh T, Kimchi A. Structure-function analysis of an evolutionary conserved protein, DAP3, which mediates TNF-alpha- and Fas-induced cell death. The EMBO Journal. 1999;18(2):353-62.

Leung RCY, Liu SS, Chan KYK, Tam KF, Chan KL, Wong L, et al. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer. Oncology reports. 2008:19(5):1339-46.

Hubertus J, Lacher M, Rottenkolber M, Müller HJ, Berger M, Stehr M, et al. Altered expression of imprinted genes in Wilms tumors. Oncology Reports. 2011;25(3):817.

Aktas S, Celebiler AC, Zadeoğluları Z, Diniz G, Kargı A, Olgun N. Expression and methylation pattern of p16 in neuroblastoma tumorigenesis. Pathology Oncology Res. 2010;16(1):1-6.

Okamoto K, Morison IM, Taniguchi T, Reeve AE. Epigenetic changes at the insulin-like growth factor II/H19 locus in developing kidney is an early event in Wilms tumorigenesis. Proceedings of the National Academy of Sciences. 1997;94(10):5367-71.

Claus R, Hackanson B, Poetsch AR, Zucknick M, Sonnet M, Blagitko D, et al. Quantitative analyses of DAPK1 methylation in AML and MDS. International Journal of Cance. 2012;131(2):138-142.

Wang LQ, Kwong YL, Wong KF, Kho CS, Jin DY, Tse E, et al. Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. Journal of Translational Medicine. 2014;12:52.

Copland M, Michie AM, Holyoake TL. Stem cells in Leukemia and other hematological malignancies. In: Majumder, S. (ed.) Stem Cells and Cancer. Springer New York: New York, NY;2009:111-136.

Chim CS, Liang R, Kwong YL: Hypermethylation of gene promoters in hematological neoplasia. Hematol Oncol. 2002;20:167-76.

Celik S, Akcora D, Ozkan T, Varol N, Aydos S, Sunguroglu A. Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients. Oncology Letters. 2015;9(1):399-404.

Wei QX, Claus R, Hielscher T, Mertens D, Raval A. Germline Allele-Specific Expression of DAPK1 in Chronic Lymphocytic Leukemia. PLoS ONE ;2013:8(1):261.

Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007;129:879-90.

Uehara E, Takeuchi S, Yang Y. Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis. Oncol Lett. 2012;3:190-192.

Mir R, Ahmad I, Javid J, Farooq S, Yadav P, Zuberi M, et al. Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia. Journal of Cancer Science Therapy, 2013.

Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, Pagano L, et al. Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood. 2004;103:698-700.